Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern-Reference-Cited by-同舟云学术

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern

Published:2021-08-25 Issue:4 Volume:10 Page:2479-2488
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Falcone Marco,Tiseo Giusy,Valoriani Beatrice,Barbieri Chiara,Occhineri Sara,Mazzetti Paola,Vatteroni Maria Linda,Suardi Lorenzo Roberto,Riccardi Niccolò,Pistello Mauro,Tacconi Danilo,Menichetti Francesco

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-021-00525-4.pdf

Reference21 articles.

1. Coppelli A, Giannarelli R, Aragona M, Penno G, Falcone M, Tiseo G, et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. Diabetes Care. 2020;43:2345–8.

2. Falcone M, Tiseo G, Barbieri G, Galfo V, Russo A, Virdis A, et al. Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome Coronavirus 2 pneumonia: a prospective observational study. Open Forum Infect Dis. 2020;7:ofaa563.

3. Falcone M, Tiseo G, Giordano C, Leonildi A, Menichini M, Vecchione A, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2021;76:1078–84.

4. Mussini C, Falcone M, Nozza SC, Parrella R, Meschiari M, et al. Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). Clin Microbiol Infect. 2021;27:389–95.

5. Stebbing J, Sánchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021;7:eabe4724.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery;Expert Opinion on Drug Discovery;2024-07-30

2. Antibody drugs targeting SARS-CoV-2: Time for a rethink?;Biomedicine & Pharmacotherapy;2024-07

3. rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering;Antibody Therapeutics;2024-07

4. Innovations and Challenges in the Development of COVID-19 Vaccines for a Safer Tomorrow;Cureus;2024-05-10

5. Comparison of bamlanivimab with or without etesevimab and casirivimab-imdevimab in clinical outcomes in patients with COVID-19: a systematic review and meta-analysis;Journal of Chemotherapy;2024-05-09